The Business Times
business-time-50

Drugmaker Takeda to zoom in on emerging markets

google-preferred-sourceAdd BT as a preferred source
Published Wed, Feb 25, 2015 · 09:50 PM

    Singapore

    ASIA'S largest drugmaker Takeda Pharmaceutical has streamlined its Singapore operations in a move that reflects its focus on emerging markets.

    Its new Biopolis office, costing an undisclosed sum, will now house its emerging-markets business unit headquarters that was previously based in Zurich, as well as its regional research and development centre and its vaccine business unit.

    TRENDING NOW

    This comes after a Citi note that lifted target prices for all Singapore banks, with a leading preference and “buy” call for DBS.

    DBS, OCBC and UOB shares hit all-time highs as sentiment improves

    Dunearn House is within walking distance to Sixth Avenue MRT station and the upcoming Turf City MRT station.

    Frasers Property launches Dunearn House condo with prices from S$2,799 psf

    In total, the IPO has raised gross proceeds of S$242 million, including commitments from 10 cornerstone investors.

    Foundation Healthcare opens 0.7% above IPO price in mainboard debut

    The eligible projects include Sun Group’s developments linked to the Asia-Pacific Economic Cooperation summit in Phu Quoc in 2027.

    Targeted credit relief: Vietnam steers funding to Vingroup, Sun Group, Masterise megaprojects

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More